Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
763 Phase 1/2 dose escalation and dose expansion study of transCon TLR7/8 agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumor malignancies: initial results from dose escalation
Compose a Response to This Article
Other responses
No responses have been published for this article.